123 related articles for article (PubMed ID: 29212208)
1. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
Oncotarget; 2017 Nov; 8(55):94040-94053. PubMed ID: 29212208
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
[TBL] [Abstract][Full Text] [Related]
3. Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
Oncotarget; 2018 Jul; 9(54):30472. PubMed ID: 30101001
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer.
Han ES; Wen W; Dellinger TH; Wu J; Lu SA; Jove R; Yim JH
Oncotarget; 2018 May; 9(36):24304-24319. PubMed ID: 29849942
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
7. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
Ogishima J; Taguchi A; Kawata A; Kawana K; Yoshida M; Yoshimatsu Y; Sato M; Nakamura H; Kawata Y; Nishijima A; Fujimoto A; Tomio K; Adachi K; Nagamatsu T; Oda K; Kiyono T; Osuga Y; Fujii T
BMC Cancer; 2018 Dec; 18(1):1201. PubMed ID: 30509235
[TBL] [Abstract][Full Text] [Related]
8. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
[TBL] [Abstract][Full Text] [Related]
9. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
10. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
Yang Y; Han K; Xie Y
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
[TBL] [Abstract][Full Text] [Related]
11. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
12. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.
Huang GS; Lopez-Barcons L; Freeze BS; Smith AB; Goldberg GL; Horwitz SB; McDaid HM
Clin Cancer Res; 2006 Jan; 12(1):298-304. PubMed ID: 16397055
[TBL] [Abstract][Full Text] [Related]
14. Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA
Tu SH; Chiou YS; Kalyanam N; Ho CT; Chen LC; Pan MH
Food Funct; 2017 Mar; 8(3):1067-1079. PubMed ID: 28145547
[TBL] [Abstract][Full Text] [Related]
15. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
16. Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(3B):2665-9. PubMed ID: 12894555
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
18. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
19. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
